Baker Bros. Advisors CADL Position
ExitedBaker Bros. Advisors exited their position in Candel Therapeutics, Inc. (CADL) in Q3 2025, after holding the stock for 4 quarters.
The position was first reported in Q4 2024 and has been tracked across 4 quarterly 13F filings.
Short interest stands at 22.9% of float with 8.6 days to cover, indicating significant bearish positioning against the stock.
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Full company profile →Short Interest
22.9%
8.6 days to cover
Baker Bros. Advisors CADL Position History
Frequently Asked Questions
Does Baker Bros. Advisors own CADL?
No. Baker Bros. Advisors exited their position in Candel Therapeutics, Inc. (CADL) in Q3 2025. They previously held the stock for 4 quarters.
How many hedge funds own CADL?
Based on the 20 specialist biotech hedge funds tracked by BiotechEdge, no tracked fund currently holds an active position in CADL.
When did Baker Bros. Advisors first buy CADL?
Baker Bros. Advisors's position in CADL was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's CADL position increasing or decreasing?
Baker Bros. Advisors completely exited their CADL position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CADLCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →